Experimental Group:ruxoltinib

2 trials

Sponsors

The Forth Affiliated Hospital Zhejiang University School of Medicine

Conditions

MyelofibrosisPolycythemia Vera

Phase 2

Efficacy and Safety of Low-dose Ruxoltinib in Patients with Lower and Intermediate Risk Polycythemia Vera ---a Single Arm, Exploratory and Prospective Study

Active, not recruitingChiCTR2200064247

The Forth Affiliated Hospital Zhejiang University School of MedicinePolycythemia Vera

Start: 2022-10-01Updated: 2023-05-15

Efficacy and Safety of Ruxoltinib in Patients with Lower Risk Myelofibrosis---a Single Arm, Exploratory and Prospective Study

Active, not recruitingChiCTR2200064250

The Forth Affiliated Hospital Zhejiang University School of MedicineMyelofibrosis

Start: 2022-10-01Updated: 2023-05-15

Related Papers

Comparing the Efficacy and Safety of Ruxolitinib in Patients with Lower and Higher Risk Myelofibrosis: A Multi-Center, Single-Arm, Exploratory and Prospective Study

Blood2024-11-051 citations

Efficacy and safety of ruxolitinib in patients with lower risk myelofibrosis: A single-arm, exploratory and prospective study.

Journal of Clinical Oncology2024-06-01